Guidelines for Dental Implant Placement in Patients Receiving Denosumab

Pharmacokinetic Profile and Rebound Risk

Denosumab’s anti‑resorptive effect declines markedly after approximately 6 months; delaying the next dose produces a rebound increase in bone turnover above baseline and raises fracture risk, with a hazard ratio of 1.9 for dosing delays of 3–6 months【@1】.
Traditional “drug holidays” that are used with bisphosphonates are contraindicated for denosumab because interruption precipitates the rebound phenomenon【@1】.
Maintaining the 6‑month dosing interval with only a brief (≤ 1 month) deviation prevents the rebound bone loss and associated fracture risk【@1】.

In osteoporosis patients receiving the standard dose of denosumab (60 mg every 6 months), the annual incidence of MRONJ is low (≈ 0–1 %), comparable to that seen with oral bisphosphonates【@6】.
In oncology patients receiving higher‑dose denosumab (120 mg monthly), the annual MRONJ incidence is higher, about 1 %【@5】.

All patients should undergo a comprehensive dental evaluation and achieve optimal oral health before initiating denosumab therapy【@4】.
When feasible, complete any invasive dental procedures (including extractions or implant planning) before the first denosumab injection【@4】.
Rigorous oral‑hygiene practices must be maintained throughout denosumab treatment to minimise oral infection risk【@4】.
Calcium supplementation (≈ 1000 mg daily) and vitamin D supplementation (800–1000 IU daily) are recommended for patients on denosumab【@4】.

Schedule dental implant placement 5–6 months after the most recent denosumab injection, coinciding with the natural decline in drug activity, and administer the subsequent denosumab dose 1 month after surgery (maximum 1‑month delay)【@3】.
This timing preserves the critical 6‑month dosing schedule while minimising the window of rebound bone turnover and reducing MRONJ risk【@3】.

Resume denosumab on the modified schedule (no more than a 1‑month postponement) after implant surgery to avoid rebound bone loss【@2】.
If MRONJ develops, denosumab must be discontinued and can only be restarted after complete resolution of the osteonecrosis【@8】.

Holding denosumab for periods longer than 1 month beyond the scheduled dose is the most hazardous error; the resulting rebound phenomenon poses a greater threat of vertebral fractures and disability than the relatively low MRONJ risk in osteoporosis patients【@2】.

For patients with multiple MRONJ risk factors (e.g., active oral infection, concurrent corticosteroid use, prior jaw radiation), consider transitioning from denosumab to a bisphosphonate 6–9 months after the last denosumab dose before proceeding with implant surgery【@8】.
Bisphosphonate therapy provides continued anti‑resorptive protection while allowing the implant procedure, and its skeletal effects persist for years after discontinuation【@3】.